Back to top
more

Fulcrum Therapeutics (FULC)

(Delayed Data from NSDQ)

$9.17 USD

9.17
1,309,815

+0.38 (4.32%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in SpringWorks (SWTX) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.

Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680

by Zacks Equity Research

Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

by Zacks Equity Research

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

by Zacks Equity Research

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

by Zacks Equity Research

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

by Zacks Equity Research

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.

J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition

by Zacks Equity Research

Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.

Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 71% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

by Zacks Equity Research

The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.

GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

by Zacks Equity Research

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

by Zacks Equity Research

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

by Zacks Equity Research

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath

by Zacks Equity Research

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.

Here's Why You Should Invest in BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

by Zacks Equity Research

Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

by Zacks Equity Research

Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

by Zacks Equity Research

Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

by Zacks Equity Research

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

by Zacks Equity Research

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

by Zacks Equity Research

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.